Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 112   

Articles published

JNJ 101.23 +0.10 (0.10%)
price chart
Johnson & Johnson's Schizophrenia Drug Wins FDA Approval
Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, developed the atypical antipsychotic Invega Trinza, which was granted priority review in January.
Johnson & Johnson''s Schizophrenia Drug Gains FDA''s ...  Nasdaq
Johnson & Johnson (JNJ) Announces FDA Approval of Invega Trinza as ...  StreetInsider.com
Johnson & Johnson Health and Wellness Solutions Study Shows "Tipping Age ...
ANN ARBOR, Mich., May 27, 2015 /PRNewswire/ -- A study conducted by Johnson & Johnson Health and Wellness Solutions, Inc. and published in PLOS ONE, an open access journal published by the Library of Science, revealed that a "tipping point" in adult ...
FitzPatrick: How Johnson & Johnson is deepening trust
Eighty years ago last month, Robert Wood Johnson sent a letter to every major industrialist in the US, arguing that businesses had a responsibility toward society and could only build real trust when it engaged all stakeholders in an authentic way ...
Johnson & Johnson and Achillion in $1.1 Billion Tie-Up
Under the exclusive global collaboration and licensing agreement, Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary becomes responsible for all costs of developing and selling the treatment regimens.
What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?  Benzinga
Achillion and Johnson amp; Johnson in $1.1B HCV Tie-Up  Zacks.com
Johnson & Johnson Seeks to Deliver 10 Blockbusters
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) might be stuck in a bit of a trading range over the past year, but that in no way reflects that its growth is at a standstill.
Johnson & Johnson proposes $300 million, 100-job expansion in Jacksonville
Johnson & Johnson Vision Care is considering a $300 million expansion to its contact lens plant in Jacksonville that would add an additional 100 jobs.
Vistakon seeking $98 million in incentives for facility expansion  Jacksonville Business Journal
Interesting August Stock Options for Johnson & Johnson
So unless Johnson & Johnson sees its shares fall 5.8% and the contract is exercised (resulting in a cost basis of $96.26 per share before broker commissions, subtracting the $1.24 from $97.50), the only upside to the put seller is from collecting that ...
Johnson & Johnson Calls On Ethicists To Weigh In On Drug Trials
Johnson & Johnson announced Thursday a first-of-its-kind partnership that will enlist a third-party review of requests for compassionate use of investigational medicines being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Johnson & Johnson Announces NYU School of Medicine Partnership To ...  MarketWatch
Houston, Johnson & Johnson May Have a Problem
First, Johnson & Johnson, better known as J&J, has a consumer healthcare division that usually delivers low single-digit growth but is high on pricing power and predictable cash flow.
FDA's New Warning About Invokana May Not Matter Much For J&J, Let ...  Trefis
The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA ...
Chicago, IL - May 26, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.